Background
Growth hormone-releasing hormone (GHRH) has a very short plasma half-life (~7 minutes) due to rapid cleavage by dipeptidyl peptidase IV (DPP-IV) at its N-terminus. This limits therapeutic utility to frequent injections or continuous infusion. CJC-1295 was developed by ConjuChem Biotechnologies as a GHRH analogue with a drug affinity complex (DAC) technology — a maleimidopropionic acid (MPA) group that covalently binds to plasma albumin, extending half-life to 6–8 days.
A critical concern with long-acting GH secretagogues was whether sustained GHRH-receptor stimulation would flatten pulsatile GH secretion and cause receptor downregulation — the same problem that limits continuous GH infusion therapy. Ionescu and Frohman investigated whether CJC-1295’s extended activity preserved normal GH pulse architecture.
Methods
21 healthy adults (mean age 38 years; BMI <30 kg/m²) received a single subcutaneous dose of CJC-1295:
- Cohort 1: 0.03 mg/kg (n=7)
- Cohort 2: 0.1 mg/kg (n=7)
- Cohort 3: Placebo (n=7)
Serial blood sampling:
- 20-minute interval GH profiling for 24 hours at baseline, day 7, and day 14
- IGF-1, IGFBP-3 measured at days 1, 2, 3, 7, 14, 21, 28
- GH pulse analysis: peak amplitude, pulse frequency, interpulse nadir, AUC
Key Findings
GH and IGF-1 Response:
| Parameter | 0.03 mg/kg | 0.1 mg/kg | Placebo |
|---|---|---|---|
| Peak GH increase | +2.3-fold | +3.1-fold | No change |
| IGF-1 increase (day 7) | +33% | +59% | −1% |
| Duration of IGF-1 elevation | 5–7 days | 7–8 days | — |
| IGFBP-3 increase | +18% | +27% | No change |
GH Pulsatility Preservation (Key Finding):
- At day 7 (peak pharmacodynamic effect), GH pulse frequency was 5.1 ± 0.4 pulses/24h in CJC-1295 group vs. 5.3 ± 0.5 in placebo — not significantly different
- Pulse amplitude increased proportionally with mean GH elevation — the normal pulse architecture was maintained with enhanced amplitude
- Interpulse nadir remained suppressed, distinguishing from continuous infusion patterns
Pharmacokinetics:
- CJC-1295 half-life: 6.0–7.9 days (albumin-bound)
- Cmax at approximately 2 hours post-injection; slow decline over 2–3 weeks
- No accumulation signal in single-dose pharmacokinetics
Safety:
- No serious adverse events
- Transient injection site reactions (redness, mild swelling)
- No hypoglycemia episodes; no IGF-1 elevation exceeding normal range
Clinical Significance
The preservation of GH pulsatility during sustained CJC-1295 activity is mechanistically important because:
- Physiologic signaling: GH’s anabolic and metabolic effects are dependent on pulsatile receptor activation; continuous stimulation produces receptor desensitization and loss of tissue responsiveness
- Reduced dosing burden: 6–8 day biological activity per injection translates to weekly or bi-weekly dosing schedules compatible with patient compliance
- IGF-1 normalization strategy: For patients with age-related GH decline (somatopause), CJC-1295 could restore IGF-1 to youthful ranges without daily injections
- IGFBP-3 co-elevation: The proportional IGFBP-3 increase moderates free IGF-1 levels, providing a physiologically buffered effect and reducing theoretical cancer risk concerns
Limitations
- Single-dose pharmacology; chronic dosing studies with repeated injections over months were not conducted in this trial
- n=21 with three arms limits statistical power for subgroup analyses
- Healthy adults only — efficacy and safety in GH-deficient adults or elderly with somatopause require separate trials
- Long-term safety of sustained modest IGF-1 elevation (including cancer risk) was not evaluated
- DAC technology results in covalent albumin binding — immunogenicity with repeated dosing requires assessment